Journal of the Medical Association of Thailand = Chotmaihet thangphaet · 2004
Endometrial thickening in postmenopausal breast cancer patients taking tamoxifen: a cross-sectional study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sinawat Supat, Chiyabutra Taweesilp
Аннотация
OBJECTIVE: To determine the prevalence of endometrial thickening (endometrial thickness > 5 mm) in postmenopausal breast cancer patients taking tamoxifen.
DESIGN: Cross-sectional descriptive study.
SETTINGS: Srinagarind Hospital, Faculty of Medicine, Khon Kaen University.
SUBJECTS: Total of 37 postmenopausal breast cancer patients receiving 20-40 mg/day of tamoxifen treatment for at least 6 months were included in the study.
METHOD: Thorough history taking and physical examination as well as transvaginal ultrasonography (TVS) were conducted in all patients.
RESULTS: Among the 37 patients included in this study, the mean age was 56.35 years. The mean body weight and mean body mass index was 60.88 kg and 26.03 kg/m2, respectively. The mean age at diagnosis of breast cancer was 51.84 years. The majority of patients (75.68%) had stage II disease while the rest of patients were diagnosed with stage III (16.22%), I (5.40%) and IV (2.70%), respectively. The mean +/- SD of endometrial thickness (ET) found in this study was 7.53 +/- 5.16 mm. The prevalence of thickened endometrium (defined as ET > 5 mm from TVS) was 59.46%. Other pelvic pathologies detected by ultrasonography were multiple small hypoechogenic areas in the endometrium (32.43%), and myoma uteri (5.41%).
CONCLUSION: The prevalence of thickened endometrium in postmenopausal breast cancer patients taking tamoxifen found in this study was extraordinarily high. Therefore it seems to be justified to propose a transvaginal ultrasound screening in all postmenopausal breast cancer patients taking tamoxifen to detect endometrial thickening and possibly pathologies which could be resulted from tamoxifen treatment.
DESIGN: Cross-sectional descriptive study.
SETTINGS: Srinagarind Hospital, Faculty of Medicine, Khon Kaen University.
SUBJECTS: Total of 37 postmenopausal breast cancer patients receiving 20-40 mg/day of tamoxifen treatment for at least 6 months were included in the study.
METHOD: Thorough history taking and physical examination as well as transvaginal ultrasonography (TVS) were conducted in all patients.
RESULTS: Among the 37 patients included in this study, the mean age was 56.35 years. The mean body weight and mean body mass index was 60.88 kg and 26.03 kg/m2, respectively. The mean age at diagnosis of breast cancer was 51.84 years. The majority of patients (75.68%) had stage II disease while the rest of patients were diagnosed with stage III (16.22%), I (5.40%) and IV (2.70%), respectively. The mean +/- SD of endometrial thickness (ET) found in this study was 7.53 +/- 5.16 mm. The prevalence of thickened endometrium (defined as ET > 5 mm from TVS) was 59.46%. Other pelvic pathologies detected by ultrasonography were multiple small hypoechogenic areas in the endometrium (32.43%), and myoma uteri (5.41%).
CONCLUSION: The prevalence of thickened endometrium in postmenopausal breast cancer patients taking tamoxifen found in this study was extraordinarily high. Therefore it seems to be justified to propose a transvaginal ultrasound screening in all postmenopausal breast cancer patients taking tamoxifen to detect endometrial thickening and possibly pathologies which could be resulted from tamoxifen treatment.